Preventing the decrease in cortical acetylcholine levels observed in AD patients is one of the strategies in the treatment of the disease, and therefore the inhibition of cholinesterase enzymes (AChE/BChE), the enzyme responsible for the metabolic hydrolysis of acetylcholine, remains an important therapeutic strategy [45,46,47]. The gene discussed is ACHE; the disease is Alzheimer disease.